UNSPSC 51286201: Fosfomycin

This classification denotes a urinary anti-infective agent with the molecular formula C3H7O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N81MY12TE, chemically known as phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2r-cis)- but more generally known as fosfomycin, which bears US NIH Compound Identifier 3417. European Medicines Agency schedules Fosfomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07797MIG.

UNSPSC 51286201 Fosfomycin is a Commodity code that, based on recent state and local procurement activity, encompasses pharmaceutical and medical supply procurement rather than fosfomycin specifically. State and local governments are using this code to solicit emergency medical supplies, naloxone products, pharmaceutical distribution programs, and generic drug procurement through multiple issuing bodies including county health departments, municipal fire departments, state health agencies, and cooperative purchasing alliances. The scope of work ranges from direct purchase of emergency response medications and first-aid consumables to establishing manufacturer-direct relationships for pharmaceutical distribution and multi-source generic drug supply agreements. Issuing bodies include Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates procurement across participating state and local government facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's invitation to bid 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first-aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer pharmacy program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers across member jurisdictions, with awards effective July 1, 2026.